Savara Inc (NASDAQ:SVRA) Given Consensus Recommendation of “Buy” by Analysts

Shares of Savara Inc (NASDAQ:SVRA) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $11.17.

A number of analysts have recently weighed in on SVRA shares. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Monday, September 9th. Oppenheimer lifted their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Savara in a report on Wednesday, August 14th. Finally, Guggenheim lifted their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th.

Savara Stock Performance

Shares of SVRA stock opened at $4.24 on Monday. The business has a 50 day simple moving average of $4.34 and a 200 day simple moving average of $4.46. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The firm has a market capitalization of $585.92 million, a price-to-earnings ratio of -11.46 and a beta of 0.97. Savara has a 12-month low of $3.12 and a 12-month high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). On average, equities research analysts anticipate that Savara will post -0.44 EPS for the current year.

Institutional Investors Weigh In On Savara

Several large investors have recently modified their holdings of SVRA. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Savara during the first quarter valued at $35,000. Choreo LLC purchased a new stake in Savara during the second quarter valued at about $59,000. DRW Securities LLC acquired a new position in shares of Savara in the second quarter worth about $62,000. Principal Financial Group Inc. increased its position in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after acquiring an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC acquired a new stake in shares of Savara during the second quarter valued at approximately $105,000. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.